In the last trading session, 1.04 million shares of the Emergent Biosolutions Inc (NYSE:EBS) were traded, and its beta was 1.60. Most recently the company’s share price was $9.01, and it changed around -$0.14 or -1.53% from the last close, which brings the market valuation of the company to $480.73M. EBS currently trades at a discount to its 52-week high of $15.10, offering almost -67.59% off that amount. The share price’s 52-week low was $1.42, which indicates that the current value has risen by an impressive 84.24% since then. We note from Emergent Biosolutions Inc’s average daily trading volume that its 10-day average is 0.87 million shares, with the 3-month average coming to 1.62 million.
Emergent Biosolutions Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.33. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended EBS as a Hold, whereas 1 deemed it a Buy, and 1 rated it as Underweight. Emergent Biosolutions Inc is expected to report earnings per share of -0.64 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Emergent Biosolutions Inc (NYSE:EBS) trade information
Instantly EBS has showed a red trend with a performance of -1.53% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 10.10 on recent trading dayincreased the stock’s daily price by 10.79%. The company’s shares are currently up 275.42% year-to-date, but still down -10.97% over the last five days. On the other hand, Emergent Biosolutions Inc (NYSE:EBS) is -2.07% down in the 30-day period. We can see from the shorts that 6.81 million shares have been sold at a short interest cover period of 4.42 day(s).
The consensus price target as assigned by Wall Street analysts is $51.5, which translates to bulls needing to increase their stock price by 82.5% from its current value. Analyst projections state that EBS is forecast to be at a low of $38 and a high of $65.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Emergent Biosolutions Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 45.56 percent over the past six months and at a 79.13% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be 5.58%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 259M in revenue for the current quarter. Analysts predict that the company’s current quarter sales will drop, forecast at -6.36%.
EBS Dividends
Emergent Biosolutions Inc’s next quarterly earnings report is expected to be released in January.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 2.09% of Emergent Biosolutions Inc shares, and 60.01% of them are in the hands of institutional investors. The stock currently has a share float of 61.29%. Emergent Biosolutions Inc stock is held by 178.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 7.3551% of the shares, which is about 3.84 million shares worth $26.18 million.
VANGUARD GROUP INC, with 7.0234% or 3.67 million shares worth $25.0 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
